M1 myeloid leukemic cells overexpressing wild-type p53 undergo apoptosis. This apoptosis can be suppressed by some cytokines, protease inhibitors, and antioxidants. We now show that induction of apoptosis by overexpressing wild-type p53 is associated with activation of interleukin-1␤-converting enzyme (ICE)-like proteases, resulting in cleavage of poly(ADP-ribose) polymerase and the proenzyme of the ICE-like protease Nedd-2. Activation of these proteases and apoptosis were suppressed by the cytokine interleukin 6 or by a combination of the cytokine interferon ␥ and the antioxidant butylated hydroxyanisole, and activation of poly(ADP-ribose) polymerase and apoptosis were suppressed by some protease inhibitors. In a clone of M1 cells that did not express p53, vincristine or doxorubicin induced protease activation and apoptosis that were not suppressed by protease inhibitors, but were suppressed by interleukin 6. In another myeloid leukemia (7-M12) doxorubicin also induced protease activation and apoptosis that were not suppressed by protease inhibitors, but were suppressed by granulocytemacrophage colony-stimulating factor. The results indicate that (i) overexpression of wild-type p53 by itself or treatment with cytotoxic compounds in wild-type p53-expressing or p53-nonexpressing myeloid leukemic cells is associated with activation of ICE-like proteases; (ii) cytokines exert apoptosis-suppressing functions upstream of protease activation; (iii) the cytotoxic compounds induce additional pathways in apoptosis; and (iv) cytokines can also suppress these other components of the apoptotic machinery.
The Ced-3 gene that is required for programmed cell death during development in the nematode Caenorhabditis elegans (1) codes for a cysteine aspartase (2, 3) homologous to the mammalian cysteine protease interleukin-1␤-converting enzyme (ICE) and other ICE-like cysteine proteases, now collectively called caspases (reviewed in refs. [4] [5] [6] [7] . Induction of apoptosis can be associated with activation of different members of the ICE family (4-7). Some ICE-like proteases activate other members of this family, creating a cascade of protease activations during apoptosis (4) (5) (6) (7) . We have previously shown that overexpression of the tumor suppressor wild-type p53 is sufficient to induce apoptotic cell death even without prior DNA damage by other agents (8) (9) (10) (11) . Wild-type p53 is also required for apoptosis induced in normal thymocytes (12) (13) (14) and bone marrow myeloid precursor cells (12) by DNAdamaging agents, but not by some other compounds (12) (13) (14) . We also showed that wild-type p53-mediated apoptosis, without prior DNA damage, can be effectively suppressed by the cytokine interleukin 6 (IL-6) (8) (9) (10) (11) and to a lesser extent by interferon ␥ (IFN-␥) (9) , by certain antioxidants (10) , and by some protease inhibitors (11) . The suppression of apoptosis by cleavage-site-directed protease inhibitors (11) indicated that ICE-like proteases are involved in wild-type p53-induced apoptosis (11) . We have now shown that overexpression of wild-type p53 activates intracellular proteases, resulting in cleavage of protein substrates of ICE-like proteases, and that suppressors of this apoptosis also suppress protease activation. We also determined whether such proteases are activated in p53 expressing and nonexpressing cells under conditions in which some protease inhibitors did not suppress apoptosis.
MATERIALS AND METHODS
Cells and Cell Culture. The cells used were mouse M1 myeloid leukemic cells, which do not express p53, transfected with plasmids containing the neomycin-resistance gene (M1-neo) or both the neomycin-resistance gene and a temperaturesensitive mutant p53 gene (M1-t-p53) (8) , and cells from another mouse myeloid leukemia, 7-M12 (15), which accumulate p53 protein after ␥-irradiation and treatment with other cytotoxic agents (10) . In the M1-t-p53 cells the temperaturesensitive p53 gene codes for a protein p53, which behaves like a tumor-suppressing wild-type p53 at 32°C and like a mutant p53 at 37°C (16) . The cells were cultured in DMEM (GIBCO) with 10% heat-inactivated (56°C, 30 min) horse serum (GIBCO) in a 10% CO 2 ͞90% air atmosphere at 37°C or 32°C.
Compounds. The compounds used to induce apoptosis were doxorubicin (Sigma) and vincristine (Teva Pharmaceutical, Jerusalem). The compounds used to suppress apoptosis were the antioxidant butylated hydroxyanisole (BHA; Sigma); the protease inhibitors N-tosyl-L-phenylalanine chloromethyl ketone (TPCK; Sigma) and benzyloxycarbonyl-Phe-Ala fluoromethyl ketone (Z-FAfmk) and benzyloxycarbonyl-Ala-Ala-Asp chloromethyl ketone (Z-AADcmk; Enzyme Systems Products, Dublin, CA); and the recombinant mouse cytokines IL-6 (obtained from J. Van Snick, Ludwig Institute for Cancer Research, Brussels), granulocyte-macrophage colony-stimulating factor (GM-CSF, Immunex), and IFN-␥ (Genzyme).
Determination of Protease Activation. Activation of ICElike proteases during apoptosis is associated with intracellular cleavage of specific protein substrates, including 116-kDa poly(ADP-ribose) polymerase (PARP) to 85-kDa and 30-kDa fragments (4-7). The 51-kDa proenzyme of the ICE-like protease Nedd-2 (neural precursor cell-expressed, developmentally down-regulated gene 2; ref. 17) is also cleaved during induction of apoptosis by certain treatments (18) , reflecting activation of Nedd-2 proteolytic activity (6) . The intracellular cleavage of these two protein substrates was determined by
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SDS͞polyacrylamide gel electrophoresis of 100 g of whole cell extract proteins prepared from cells at different times after initiation of apoptosis-inducing treatments as described (10), followed by Western blotting using a 1:200 dilution of antibody to the amino-terminal portion of mouse PARP (A20) or the p12 carboxy-terminal portion of mouse Nedd-2 (C20) (Santa Cruz Biotechnology). After 5 washes in TBS blocking buffer (50 mM Tris⅐HCl, pH 7.5͞150 mM NaCl) containing 0.2% Tween 20 and 5% low-fat milk, the blots were further incubated with a 1:2000 dilution of horseradish peroxidaseconjugated anti-IgG secondary antibody (Santa Cruz Biotechnology), washed five times in TBS containing 0.2% Tween 20 and developed with the enhanced chemiluminescence detection kit (ECL; Amersham). Bands corresponding to the appropriate proteins or protein fragments were visualized after exposing the blots to Fuji RX medical x-ray film. After determination of PARP cleavage, the same blots were stripped and then reprobed with anti-Nedd-2 antibody.
RESULTS
Cleavage of PARP and Pro-Nedd-2 in Apoptosis Induced by Overexpression of Wild-Type p53. M1-t-p53 cells overexpress the Val-135 temperature-sensitive mutant p53 protein when cultured at 37°C (8) . After transfer of cells to 32°C, the conformation of the mutant protein changes so that it behaves like wild-type p53 (16) , and this is sufficient to induce apoptotic cell death (8) (9) (10) (11) . While expression of a p53-inducible gene such as p21͞WAF1 is induced and a p53-suppressible gene, c-myc, is suppressed within 1-2 hr after M1-t-p53 cell transfer to 32°C (9, 19) , apoptotic cells start to be recognizable after about 10 hr (8, 10) . Analysis of PARP and pro-Nedd-2 in cells cultured at 32°C has shown that the 116-kDa and 51-kDa proteins were cleaved to produce fragments of 30 kDa (aminoterminal) and 12 kDa (carboxyl-terminal), respectively. These fragments were barely detectable in cells cultured at 37°C, and after cell transfer to 32°C showed a readily detectable increase at 10 hr (Fig. 1) . This indicates that induction of apoptosis by overexpression of wild-type p53, even without DNA damage by another agent, is sufficient to activate ICE-like proteases.
Suppression of Protease Activation by Different Suppressors of Wild-Type p53-Induced Apoptosis. Addition of 10 ng͞ml IL-6, which suppresses p53-mediated apoptosis in M1-t-p53 cells cultured at 32°C (8) (9) (10) (11) , suppressed production of the 30-kDa PARP and 12-kDa Nedd-2 fragments after culture at 32°C (Fig. 2) . The cytokine IFN-␥, the antioxidant BHA, and the protease inhibitor Z-AADcmk also suppressed wildtype p53-induced apoptosis in M1-t-p53 cells, but they were less effective than IL-6 in suppressing apoptosis (9) (10) (11) . IFN-␥, BHA, and Z-AADcmk also showed a lower protective effect on PARP cleavage (Fig. 2) . The results with two other apoptosis-suppressing protease inhibitors, TPCK and ZFAfmk (11), were similar to those obtained with Z-AADcmk. Combined treatment with IFN-␥ and BHA, or IFN-␥, BHA, and Z-AADcmk, which were almost as effective as IL-6 in protection against wild-type p53-induced apoptosis (10, 11) , also effectively suppressed production of the 30-kDa PARP and the 12-kDa Nedd-2 fragments (Fig. 2) . Although IFN-␥, BHA, or the protease inhibitors by themselves suppressed cleavage of PARP, they did not suppress production of the 12-kDa Nedd-2 fragment (Fig. 2) .
Activation of Proteases by Cytotoxic Compounds in Other p53-Expressing and in p53-Nonexpressing Myeloid Leukemic Cells. Myeloid leukemic 7-M12 cells do not express detectable p53 protein, but addition of doxorubicin induces accumulation of endogenous p53 protein, and this is associated with induction of apoptosis starting at 3 hr (10). Unlike M1-t-p53 cells induced to undergo apoptosis by overexpression of wild-type p53 at 32°C, doxorubicin-induced apoptosis in 7-M12 cells was not suppressed by different protease inhibitors (11) . Apoptosis induced in 7-M12 cells by 1.5 g͞ml doxorubicin was also associated with cleavage of PARP and pro-Nedd-2 (Fig. 3) . The cytokine GM-CSF, which suppressed induction of apoptosis by doxorubicin in 7-M12 cells (10, 11) , also suppressed cleavage of PARP and pro-Nedd-2 (Fig. 3) . The protease inhibitor Z-FAfmk, which did not suppress this induction of apoptosis by doxorubicin (11), showed no suppression of cleavage of PARP or pro-Nedd-2 (Fig. 3) , and similar results were obtained with TPCK. These data indicate that although induction of apoptosis by doxorubicin in the p53-expressing 7-M12 cell was not suppressed by some protease inhibitors (11), induction of apoptosis by this DNA-damaging agent in 
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Medical Sciences: Lotem and Sachs Proc. Natl. Acad. Sci. USA 94 (1997) these cells was associated with activation of PARP-and pro-Nedd-2-cleaving proteases. We also determined whether PARP-and pro-Nedd-2-cleaving proteases are activated in M1-neo myeloid leukemic cells, which do not express p53 before or after treatment with cytotoxic agents (11) . As in doxorubicin-treated 7-M12 cells, apoptosis induced in M1-neo cells by 60 ng͞ml vincristine was associated with cleavage of PARP and pro-Nedd-2 (Fig. 4) . Activation of proteases in M1-neo cells by vincristine was suppressed by IL-6 (Fig. 4) , which protected the cells from vincristine-induced apoptosis (11, 20) , but there was no suppression of cleavage of PARP and pro-Nedd-2 by TPCK (Fig.  4) or by Z-FAfmk, which did not protect the cells from this apoptosis (11) . Similar results were obtained in M1-neo cells treated with 1.2 g͞ml doxorubicin (Fig. 5) . PARP-and pro-Nedd-2-cleaving proteases are thus activated during apoptosis mediated by wild-type p53-dependent and p53-independent pathways, apoptosis-suppressing cytokines such as IL-6 or GM-CSF, and a combination of IFN-␥ with the antioxidant BHA suppress protease activation, but addition of various protease inhibitors by themselves was not always sufficient to suppress apoptosis. This indicates that the apoptosis-suppressing cytokines can suppress other components of the apoptotic machinery in addition to suppressing activation of ICE-like proteases.
DISCUSSION
The present results have shown that overexpression of wildtype p53 in M1 myeloid leukemic cells without prior DNA damage by another agent is sufficient for activation of intracellular proteases, resulting in cleavage of PARP and proNedd-2 proteins. ICE-like proteases are activated from their proenzymes by cleavage after aspartyl residues at sites similar to ICE-like substrates, generating fragments of 10-20 kDa (p10-p20), which then assemble into proteolytically active heterodimeric or tetrameric enzymes (4-7). Activation of Nedd-2 proteolytic activity follows assembly of a p12 carboxylterminal subunit with another p19 subunit (6) . It is, therefore, suggested that the 12-kDa carboxyl-terminal Nedd-2 fragment cleaved from the 51-kDa pro-Nedd-2 during wild-type p53-mediated apoptosis in the present experiments reflects acti- vation of the Nedd-2 protease. This activation of Nedd-2 may follow its physical interaction with the ubiquitously expressed death-domain-containing adaptor molecule R A IDD͞ CRADD (21, 22) , similar to the interaction between the ICE-like protease MACH͞FLICE͞caspase 8 with the adaptor molecule FADD͞MORT1 in the FAS and tumor necrosis factor pathways to apoptosis (23, 24) . Cleavage of PARP was described as being carried out by the ICE-like protease prICE (25) , also known as CPP32, apopain, yama, or caspase 3 (4-7). CPP32 Ϫ/Ϫ mice showed abnormalities in the apoptotic pathway during neuronal development, indicating the involvement of this ICE-like protease in this apoptotic process (26) . Further experiments indicated that PARP can also be cleaved by other ICE-like proteases, including ICH-1͞Nedd-2 (caspase 2), ICE-rel II (caspase 4), Mch 3 (caspase 7), and ICE-LAP6 (caspase 9) (4-7). PARP was also shown to be cleaved during induction of apoptosis by different stimuli even in thymocytes from CPP32 Ϫ/Ϫ mice (26) . It is thus possible that wild-type p53-induced cleavage of PARP in M1-t-p53 cells was mediated, at least in part, by activated Nedd-2, although other proteases of the ICE family may also be involved in this PARP cleavage.
Various cytokines can suppress apoptosis (reviewed in refs. [27] [28] [29] . We have now shown that suppression of wild-type p53-induced apoptosis by IL-6 results in suppression of cleavage of PARP and pro-Nedd-2. IL-6 can thus act upstream of activation of ICE-like proteases in the apoptotic pathway (Fig.  6 ). Our results have also shown that different cytotoxic agents can activate ICE-like proteases during apoptosis in p53-expressing and p53-nonexpressing cells and that this protease activation and apoptosis are suppressed by the cytokines GM-CSF or IL-6. Different cytokines can thus suppress activation of cytotoxic compound-induced p53-dependent and p53-independent pathways of apoptosis by acting at a point upstream of activation of ICE-like proteases, as in apoptosis induced by overexpression of wild-type p53 (Fig. 6) .
We have previously shown that induction of apoptosis by overexpression of wild-type p53 as well as by certain DNAdamaging agents involves an oxidative pathway that can be suppressed by different antioxidants, including BHA (10). We have now found that BHA also suppresses PARP cleavage induced by overexpression of wild-type p53, but not as effectively as the cytokines IL-6 or GM-CSF. This indicates that BHA also acts upstream of protease activation (Fig. 6 ). This agrees with other results showing that antioxidants can suppress activation of PARP cleavage (30) . However, unlike suppression of pro-Nedd-2 cleavage by these cytokines, we did not observe suppression of cleavage of pro-Nedd-2 by BHA or protease inhibitors. It is therefore possible that activation of different proteases during apoptosis can be selectively regulated by different apoptosis-suppressing compounds acting through different pathways. This may also explain the lower apoptosis-suppressing effect of BHA compared with IL-6 or GM-CSF, and the cooperative activity of BHA, IFN-␥, and different protease inhibitors in suppression of protease activation and apoptosis.
Unlike apoptosis induced by overexpression of wild-type p53, induction of apoptosis by doxorubicin or vincristine, which was also associated with protease activation, was not suppressed by the protease inhibitors Z-VADfmk, Z-FAfmk, Z-AADcmk, or TPCK (11). These results indicate that apoptosis induced by these cytotoxic compounds is associated with activation of additional components of apoptosis that are not suppressed by the protease inhibitors used in our experiments. But cytokines can suppress these other components of the apoptotic machinery. The ability to suppress different components of apoptosis is supported by the ability of the proteaseinhibiting viral proteins CrmA and p35 to suppress apoptosis induced by some but not other apoptosis-inducing agents (31) and by the observation that overexpression of Bcl-2 and Bcl-X L , which act upstream of protease activation (32-34), does not always prevent apoptosis (33, 34) .
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